Fractyl Logo

Our Science

Shifting the therapeutic focus to the root causes of T2D and obesity

FRACTYL HEALTH ASSETS ARE POTENTIALLY POSITONED TO TARGET PREVIOUSLY UNADDRESSABLE CATEGORIES IN T2D AND OBESITY

1. FDA Draft Guidance: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention February 2008 (withdrawn), Section V.B.5 Prevention of Type 2 Diabetes Mellitus 2. Buse et al Diabetes Care. 2009 32:2133-2135. 3. FDA Guidance for Industry Developing Products for Weight Management February 2007. 4. Adapted from Hatoum et al JAMA Surgery Feb 2016.

FRACTYL HEALTH DEVELOPMENT PIPELINE AIMS TO TRANSFORM THE ENTIRE METABOLIC SPECTRUM

1. Revita has been granted Breakthrough Device designation for the hydrothermal ablation of the duodenal mucosa to improve glycemic control and eliminate insulin needs in T2D patients inadequately controlled on long-acting insulin; and CE mark obtained from EU and UK in 2016 for Revita for the improvement of glycemic control in patients with inadequately controlled T2D despite oral and/or injectable glucose lowering medications and/or long-acting insulin.
2. The Germany Real World Registry study is a post-market, clinical follow-up study in real-world patients with inadequately controlled T2D on at least one ADA.
3. The Revitalize-1 study is a pivotal study in patients with inadequately controlled T2D despite being on up to three ADAs and daily insulin.
4. Product candidates under out Rejuva gene therapy platform will undergo Phase 1, Phase 2 and Phase 3 clinical trials. IND = Investigational New Drug Application with FDA or comparable regulatory body; IDE = Investigational Device Exemption.

OUR PRESENTATIONS, SCIENTIFIC POSTERS, AND PUBLICATIONS

2023
DDW, 2023

Duodenal Mucosal Resurfacing Procedure Training and Implementation

Galvani, et al. presented poster at Digestive Disease Week (DDW) 2023, Chicago, IL USA, May 2023

View Poster
2022
UEGW, 2022

Enhanced β-cell function and improved insulin sensitivity after Revita® Duodenal Mucosal Resurfacing in patients with T2D

Busch, et al. presented poster at United European Gastroenterology Week (UEGW), Vienna, Austria, Oct 2022

View Poster
2021
Journal of Diabetes Science and Technology, October 2021.

A Gut-Centric Model of Metabolic Homeostasis

Rajagopalan, et al.

View Publication
DDW, May 2021

Changes in Incretins Bile acids and the Microbiome after duodenal mucosal resurfacing in patients with Type 2 Diabetes

Meiring, et al. presented at Digestive Disease Week (DDW) 2021, Virtual, May 2021

View Presentation
2020
ISMRM & SMRT, 2020.

Proton-density fat fraction-derived R2* liver iron concentration – an exploratory study of Revita-2 phase II trial data

Chouhan, et al. presented at ISMRM & SMRT Virtual Conference & Exhibition. Virtual, August 2020.

View Presentation
ADA, 2020.

Durable Glycemic Improvements After Duodenal Mucosal Resurfacing (DMR) in Patients with Type 2 Diabetes (T2D): 48-week Results From the REVITA-2 European Cohort

Mingrone, et al. presented poster at 80th American Diabetes Association Scientific Sessions (ADA) Virtual, June 2020.

View Poster
ESGAR, 2020.

MRI liver proton density fat fraction in patients with the type 2 diabetes mellitus following treatment with Duodenal Mucosal Resurfacing – results from a randomised, double-blind, sham-controlled, prospective, multicenter study

Chouhan, et al. presented poster at European Society of Gastrointestinal and Abdominal Radiology 2020 Virtual Congress (ESGAR). Amsterdam, The Netherlands, May 2020.

View Poster
ESGAR, 2020.

Serum ferritin levels in patients with non-elevated Proton-Density Fat Fraction-derived R2* Liver Iron concentration – an explanatory study of Revita-2 phase II trial data

Chouhan, et al. presented poster at European Society of Gastrointestinal and Abdominal Radiology 2020 Virtual Congress (ESGAR). Amsterdam, The Netherlands, May 2020.

View Poster
2019
DTM, 2019

Duodenal Mucosal Resurfacing (DMR) for the Treatment of Type 2 Diabetes

Lopez-Talavera, et al. presented at Diabetes Technology Meeting (DTM). North Bethesda, MD, November 2019.

View Presentation
DTM, 2019

Durable Glycemic and Hepatic Improvements After Duodenal Mucosal Resurfacing in Patients With Type 2 Diabetes

van Baar, et al. presented poster at Diabetes Technology Meeting (DTM). North Bethesda, MD, November 2019.

View Poster
ObesityWeek, 2019

Diet-Induced Intestinal Mucosal Disequilibrium Contributes to Insulin-Resistant Metabolic Disease

West, et al. presented poster at ObesityWeek 2019. Las Vegas, NV, November 2019.

View Poster
UEGW, 2019

Duodenal mucosal resurfacing combined with GLP-1 eliminates insulin therapy and improves metabolic health in type 2 diabetes

van Baar, et al. presented at United European Gastroenterology Week 2019 (UEGW). Barcelona, Spain, October 2019.

View Presentation
ADA, June 2019

Duodenal mucosal resurfacing (DMR) combined with GLP-1 receptor agonism may eliminate insulin treatment while maintaining glycemic control and improving overall metabolic health in type 2 diabetes

Meiring, et al. presented poster at 79th American Diabetes Association Scientific Sessions (ADA). San Francisco, California, USA, June 2019.

View Poster
WCITD, April 2019.

Endoscopic Duodenal Mucosal Resurfacing

Hopkins. presented at 4th World Congress on Interventional Therapies for Type 2 Diabetes (WCITD). New York City, NY, USA, April 2019.

View Presentation
WCITD, 2019

Duodenal Mucosal Resurfacing Improves Glycemic, Lipid and Hepatic Fat Fraction Measures in Type 2 Diabetes

Hopkins, et al. presented poster at 4th World Congress on Interventional Therapies for Type 2 Diabetes (WCITD). New York City, NY, USA, April 2019.

View Poster
2018
AASLD, November 2018

Reduction in Liver Fat in Patients with Type 2 Diabetes Following Treatment with Duodenal Mucosal Resurfacing

Maggs, et al. presented poster at American Association for the Study of Liver Diseases (AASLD). San Francisco, Calif., USA, November 2018.

View Poster
NASH, July 2018.

Duodenal mucosal resurfacing improves lipotoxic stress, mitochondrial function, aerobic metabolism, and gluconeogenic drive in type 2 diabetes

deGravelle, et al. presented poster at 4th Paris Nash Meeting. Paris, France, July 2018.

View Presentation
NASH, July 2018.

Duodenal Mucosal Resurfacing Reduces Liver Fat in Patients with Type 2 Diabetes

Maggs, et al. presented poster at 4th Paris Nash Meeting. Paris, France, July 2018.

View Presentation
DDW, June 2018.

Successful Implementation Of Duodenal Mucosal Resurfacing Endoscopic Procedure Across Multiple Centers in a Study of Type 2 Diabetes Subjects

Haidry, et al. presented poster at Digestive Disease Week – Monumental Developments in Science & Medicine (DDW). Washington, DC, USA, June 2018

View Poster
ADA, June 2018.

Westernized Diet-induced Insulin Resistance in Mice is Associated with Focal Duodenal Hyperplasia Westernized Diet-induced Insulin Resistance in Mice is Associated with Focal Duodenal Hyperplasia

Ghosh, et al. presented poster at 78th American Diabetes Association Scientific Sessions (ADA). Orlando, Florida, USA, June 2018.

View Poster
ADA, June 2018

Duodenal Mucosal Resurfacing Elicits Improvement in Glycemic and Hepatic Parameters in Type 2 Diabetes: 1 Year Multicenter Study Results

van Baar, et al. presented poster at 78th American Diabetes Association Scientific Sessions (ADA). Orlando, Florida, USA, June 2018.

View Poster
2017
AHA, November 2017

The Economic Burden of Insulin Resistance, Obesity, and Cardiovascular Disease in Medicare Beneficiaries 65 Years of Age and Older

Sacks, et al. presented poster at American Heart Association Meeting (AHA). Anaheim, Calif., USA, November 2017.

View Poster
AASLD, October 2017

Improvement in Hepatic Transaminases Over 12 Months After Single Procedure Duodenal Mucosal Resurfacing in Type 2 Diabetes Patients

van Baar, et al. presented poster at American Association for the Study of Liver Diseases (AASLD). Washington, DC, USA, October 2017.

View Poster
EASD, September 2017

Duodenal Mucosal Resurfacing demonstrates sustained improvement in glycaemic parameters in type 2 diabetes: 12 month data

van Baar, et al. presented poster at 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD). Lisbon, Portugal, September 2017.

View Poster
NASH, July 2017

Duodenal Mucosa: A Target for Treating Metabolic Liver Disease in NASH and T2D

Rajagopalan presented at 3rd Paris Nash Meeting. Paris, France, July 2017.

View Presentation
Gastrointestinal Endoscopy Clinics of North America, 27(2): 299-311, April 2017.

Hydrothermal Duodenal Mucosal Resurfacing Role in the Treatment of Metabolic Disease

Cherrington, et al.

View Publication
2016
AASLD, November 2016.

Endoscopic duodenal mucosal resurfacing (DMR) improves insulin sensitivity, hepatic transaminase levels and anti-inflammatory markers in subjects with type 2 diabetes

Rajagopalan, et al. presented poster at American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, USA, November 2016.

View Poster
AASLD, November 2016

A single endoscopic duodenal mucosal resurfacing procedure exerts a sustained improvement in hepatic transaminase levels in a cohort of type 2 diabetes patients

van Baar, et al. presented poster at American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, USA, November 2016.

View Poster
TOS, October 2016

Duodenal mucosal hydrothermal ablation: a new procedure designed for metabolic gain

Maggs presented at The Obesity Society (TOS). New Orleans, LA, USA, October 2016

View Presentation
UEGW, October 2016

Endoscopic Duodenal Mucosal Resurfacing treatment for type 2 diabetes: Early multicenter experience

van Baar, et al. presented poster at United European Gastroenterology Week (UEGW). Vienna, Austria, October 2016

View Poster
ADA, June 2016

Endoscopic Duodenal Mucosal Resurfacing (DMR) Improves Metabolic Measures in Type 2 Diabetes: First-in-Human Study 6-Month Data

Cherrington, et al. presented at 76th American Diabetes Association (ADA). New Orleans, Louisiana, USA, June 2016. [Oral]

View Presentation
DDW, May 2016.

Endoscopic Duodenal Mucosal Resurfacing (DMR) Improves Glycemic and Hepatic Parameters in Patients with Type 2 Diabetes: Data from a First-in-Human Study

Rajagopalan, et al. presented at Digestive Disease Week (DDW). San Diego, Calif, USA, May 2016.

View Presentation
DDW, May 2016

Early experience of Duodenal Mucosal Resurfacing treatment for Type 2 Diabetes when expanding from single to multiple sites

van Baar, et al. presented at Digestive Disease Week (DDW). San Diego, Calif, USA, May 2016

View Presentation
EASL, April 2016.

Endoscopic duodenal mucosal resurfacing (DMR) improves metabolic measures including hepatic transaminase levels in patients with type 2 diabetes (T2D): Data from a first-in-human study

Rajagopalan, et al. presented poster at The International Liver Congress-European Association for the Study of the Liver (EASL). Barcelona, Spain, April 2016.

View Poster
GTC Diabetes Summit, April 2016.

Duodenal mucosa: a target for treating metabolic disease

Rajagopalan, et al. presented at 9th Diabetes Drug Discovery & Development Conference-GTC Diabetes Summit. Boston, Massachusetts, USA, April 2016.

View Presentation
EASL, April 2016.

Endoscopic Duodenal Mucosal Resurfacing (DMR) Improves Metabolic Measures, Including Hepatic Transaminase Levels, in Patients with Type 2 Diabetes: Data from a First-in-Human Study

Rajagopalan, et al. presented at The International Liver Congress-European Association for the Study of the Liver (EASL). Barcelona, Spain, April 2016.

View Presentation
2015
WCIRS, December 2015.

Early clinical experience of duodenal mucosal resurfacing (DMR), a new endoscopic approach to treating type 2 diabetes

Cherrington, et al. presented poster at 13th World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRS). Los Angeles, Calif., USA, December 2015.

View Poster
UEGW, October 2015.

Duodenal mucosal resurfacing (DMR) as a new endoscopic treatment for type 2 diabetes (T2D): Safety and proof-of principle cohort study

Cherrington, et al. presented poster at United European Gastroenterology Week (UEGW). Barcelona, Spain, October 2015.

View Poster
WCITT2D, September 2015.

Duodenal mucosal resurfacing (DMR) as a new endoscopic treatment for type 2 diabetes (T2D): Safety and proof-of principle cohort study

Cherrington, et al. presented poster at Third World Congress on Interventional Therapies for Type 2 Diabetes (WCITT2D). London, UK, September 2015.

View Poster
2014
EASD, September 2014.

Evaluation of the Duodenal Mucosal Resurfacing (DMR) for the Treatment of Type 2 Diabetes

Holleman. presented at 50th Annual Meeting of the European Association for the Study of Diabetes (EASD). Vienna, Austria, September 2014.

View Presentation
EASD, September 2014.

Metabolic Surgery for Type 2 Diabetes – Window into Pathophysiology

Rubino. presented at 50th Annual Meeting of the European Association for the Study of Diabetes (EASD). Vienna, Austria, September 2014.

View Presentation
IFSO, August 2014.

Duodenal Mucosal Resurfacing A New Procedural Therapy for Type 2 Diabetes

Galvao, et al. presented at World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Montreal, Canada, August 2014.

View Presentation
2023
WCIRDC, 2023

Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity

Liou, et.al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease, Universal City, CA, Dec 2023

View Presentation
EASD, 2023

Pancreatic Gene Therapy Durably Improves Glycaemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes

Rajagopalan, et al. presented at European Association for the Study of Diabetes (EASD) 2023, Hamburg, German, October 2023

View Presentation
ADA, 2023

Pancreatic Gene Therapy Durably Improves Glycemia and Delays Disease Progression in a Murine Model of Type 2 Diabetes

Rajagopalan, et al. presented at American Diabetes Association 2023, San Diego, CA, June 2023

View Presentation
ASGCT, 2023

A Pancreatic Gene Therapy Delivery Platform for the Treatment of Type 2 Diabetes

Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023

View Presentation
ASGCT, 2023

Local Delivery and Tissue Restricted Expression to Optimize Therapeutic Profile for Pancreatic Gene Therapy

Rajagopalan, et al. presented at American Society of Gene and Cell Therapy, Los Angeles, CA, May 2023

View Presentation
2022
WCIRDC, 2022

AAV-Mediated Pancreatic Gene Therapy for Type 2 Diabetes

Liou, et al. presented at World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC), Universal City, CA, Dec 2022

View Presentation
2017
AHA, November 2017

The Economic Burden of Insulin Resistance, Obesity, and Cardiovascular Disease in Medicare Beneficiaries 65 Years of Age and Older

Sacks, et al. presented poster at American Heart Association Meeting (AHA). Anaheim, Calif., USA, November 2017.

View Poster

Erase T2D

Advancing research on the role of the gut in metabolic disease

Led by world-renowned experts in metabolic disease, the EraseT2D task force shares Fractyl Health’s mission to build evidence, understand, and ultimately eradicate metabolic disease.

The Erase T2D task force builds on decades of discovery that have clearly identify the critical role of the gut as a regulator of metabolic disease. The signaling mechanisms between the gut and the rest of the body are numerous and not yet fully understood. The task force is charged with advancing research on the role of the gut in metabolic disease to catalyze future discoveries that may inform how diabetes can be better understood and ultimately erased.
This initiative, funded by Fractyl Health, is meant to spur the kind of innovative thinking and fundamental breakthroughs that will point the way toward a world without type 2 diabetes.

Erase Task Force

The ERASE T2D Task Force is comprised of the following members:

Alan Cherrington,
Ph.D.
(co-chair)

Professor of Molecular Physiology & Biophysics, Professor of Medicine, and Jacquelyn A. Turner and Dr. Dorothy J Turner Chair in Diabetes Research at Vanderbilt University School of Medicine

Harith Rajagopalan,
M.D., Ph.D.
(co-chair)

Co-founder and CEO of Fractyl Health

Dave D’Alessio,
M.D.

Professor of Medicine and Chief of Division of Endocrinology and Metabolism at Duke University School of Medicine

Geltrude Mingrone,
M.D., Ph.D.

Professor of Diabetes and Nutrition at King’s College, London; Associate Professor of Internal Medicine at Catholic University of Rome

Randy Seeley,
Ph.D.

Professor of Surgery and Director of Michigan Nutrition Obesity Research Center at Michigan School of Medicine

Timothy Kieffer,
Ph.D.

Chief Scientific Officer of Fractyl Health